Last reviewed 2026-04-22 · How we verify

PCV10 full dose

PCV10 is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 10 serotypes of Streptococcus pneumoniae.

PCV10 is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 10 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in infants and children, Prevention of pneumococcal pneumonia and otitis media.

At a glance

Mechanism of action

The vaccine contains polysaccharide capsules from 10 pneumococcal serotypes conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent responses. This conjugation allows the vaccine to elicit both humoral and cellular immune responses, providing protection against invasive pneumococcal disease caused by these serotypes. The vaccine is administered to generate protective antibody titers against the included serotypes.

Approved indications

• Prevention of invasive pneumococcal disease in infants and children
• Prevention of pneumococcal pneumonia and otitis media

Common side effects

• Injection site erythema
• Injection site swelling
• Fever
• Irritability
• Drowsiness

Key clinical trials

• Mass Campaigns With Fractional Dose Pneumococcal Vaccines in Sub-Saharan Africa (fPCV) (PHASE4)
• The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• PCV10 full dose CI brief — competitive landscape report
• PCV10 full dose updates RSS · CI watch RSS
• Epicentre portfolio CI